Clinical Trial Update: Phase I Trial: 68Ga-NODAGA-E(c[RGDyK])2 Positron Emission Tomography for Imaging Angiogenesis in Primary and Metastatic Tumor Lesions in Humans [Phase 1]

View source ↗

Summary

Phase I imaging trial evaluating 68Ga-NODAGA-E(cRGDyK)2 PET for assessing angiogenesis in primary and metastatic tumors; trial status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Neuroendocrine Carcinoma
• Ovarian Cancer

Drugs mentioned

• 68Ga-NODAGA-E(cRGDyK)2

Snippet

Sponsor: Rigshospitalet, Denmark | Conditions: Neuroendocrine Carcinoma, Breast Cancer | Phase 1 | Status: UNKNOWN